These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22896656)

  • 21. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
    Jain S; Wang X; Chang CC; Ibarra-Drendall C; Wang H; Zhang Q; Brady SW; Li P; Zhao H; Dobbs J; Kyrish M; Tkaczyk TS; Ambrose A; Sistrunk C; Arun BK; Richards-Kortum R; Jia W; Seewaldt VL; Yu D
    Cancer Res; 2015 Nov; 75(22):4863-75. PubMed ID: 26383165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
    Fang H; Jin J; Huang D; Yang F; Guan X
    Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
    Chiu LY; Hsin IL; Tsai JN; Chen CJ; Ou CC; Wu WJ; Sheu GT; Ko JL
    J Cell Physiol; 2021 Feb; 236(2):1148-1157. PubMed ID: 32686156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
    Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
    Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.
    Andersen CL; Sikora MJ; Boisen MM; Ma T; Christie A; Tseng G; Park Y; Luthra S; Chandran U; Haluska P; Mantia-Smaldone GM; Odunsi K; McLean K; Lee AV; Elishaev E; Edwards RP; Oesterreich S
    Clin Cancer Res; 2017 Jul; 23(14):3802-3812. PubMed ID: 28073843
    [No Abstract]   [Full Text] [Related]  

  • 28. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
    Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
    PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
    Zhang L; Cui J; Leonard M; Nephew K; Li Y; Zhang X
    PLoS One; 2013; 8(7):e70641. PubMed ID: 23936234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
    Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
    FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
    Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
    Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
    Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
    Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
    Hou JY; Rodriguez-Gabin A; Samaraweera L; Hazan R; Goldberg GL; Horwitz SB; McDaid HM
    PLoS One; 2013; 8(2):e54103. PubMed ID: 23390495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.